Here is a sample of announcements from today alone regarding the pharmaceutical industry in India:
First, UK-based Reckitt Benckiser is acquiring Paras Pharmaceuticals for $726 million. Paras makes a variety of over-the-counter products for pain and cough and cold.
We are looking at partnerships with Indian firms that have their own R&D and manufacturing capability, where we can take advantage and also bring our innovative capabilities. So, we want a mutually beneficial partnership with local companies.
Lastly, Mumbai-based Sun Pharma is going the other way, by looking for acquisitions in the US.